| Simvastatin Suppresses Apoptosis in Vulnerable Atherosclerotic Plaques Through Regulating the Expression of p(53), Bcl-2 and Bcl-xL. | |
| | |
MedLine Citation:
|
PMID: 22038096 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE: Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has antioxidant and anti-inflammatory properties that are independent of lipid-lowering abilities. This experiment was carried out to explore the effects of simvastatin on apoptosis in vulnerable atherosclerotic plaques of apoE-deficient mice. METHODS AND RESULTS: Eight weeks-old apoE(-/-) mice were fed a Western-type diet. Vulnerable atherosclerotic lesions were formed in the branchiocephalic artery at the age of 30-weeks, before simvastatin administration for 8 weeks. Simvastatin did neither affect the levels of plasma glucose and lipids, nor the size of atherosclerotic lesions. Analysis of plaque composition showed that simvastatin decreased the area of lipid core and increased the amounts of macrophages and smooth muscle cells in atherosclerotic plaques of apoE(-/-) mice. In addition, simvastatin down-regulated the expression of vascular cell adhesion molecule-1 (VCAM-1) by both inhibition of nuclear factor kappa B (NF-кB) activation and suppression of the expression of the receptor for advanced glycation end products (RAGE). Moreover, we found that simvastatin administration led to reduced TUNEL-positive cells in the aortic root lesions, accompanied by up-regulation of Bcl-2 and Bcl-xL expression, and decreased P(53) expression as shown by Western blot. CONCLUSION: In the present study, we show novel data to suggest that simvastatin could suppress apoptosis in vulnerable atherosclerotic plaques of apoE(-/-) mice by regulating the expression of apoptosis-related proteins, such as p(53), Bcl-2 and Bcl-xL. |
| | |
Authors:
|
Weiwei Qin; Yonggang Lu; Chengyan Zhan; Tao Shen; Lin Dou; Yong Man; Shu Wang; Chuanshi Xiao; Yunfei Bian; Jian Li |
Related Documents
:
|
18567096 - Pleiotropic effects of bombesin and neurotensin on intestinal mucosa: not just trefoil ... 7883396 - Biochemical mechanisms to explain immunosuppression in well-trained and overtrained ath... 20415856 - 99th dahlem conference on infection, inflammation and chronic inflammatory disorders: p... 19504616 - Prevention of tnbs-induced colitis by different lactobacillus and bifidobacterium strai... 15780486 - Inflammation may be a bridge connecting hypertension and atherosclerosis. 12960176 - Phosphatidic acid regulates systemic inflammatory responses by modulating the akt-mamma... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-10-26 |
Journal Detail:
|
Title: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy Volume: - ISSN: 1573-7241 ISO Abbreviation: - Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-10-31 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8712220 Medline TA: Cardiovasc Drugs Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing, 100730, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Colistin A and colistin B among inhibitory substances of Paenibacillus polymyxa JB05-01-1.
Next Document: SIRT1 is required for long-term growth of human mesenchymal stem cells.